

TABLE OF CONTENTS

Book 11

Preface	i	Clinical Presentation	8
Editorial Board	ii	Treatment	9
Book 11 Panel	iii	Blood Agents	9
Disclosure of Potential Conflicts of Interest	vii	Clinical Presentation	9
Continuing Education and Program Evaluation		Treatment	9
Instructions	viii	Choking Agents	10
Roles of ACCP and BPS	xi	Clinical Presentation	10
		Treatment	10
		Nerve Agents	10
		Clinical Presentation	11
		Treatment	11
		Ricin	11
		Clinical Symptoms	12
		Treatment	12
		Radiological Agents	12
		Clinical Symptoms	12
		Treatment	12
		Institutional Preparedness	13
		Conclusion	15
		Annotated Bibliography	15
		Self-Assessment Questions	17
		ENDOCRINE INTERVENTIONS IN THE	
		CRITICALLY ILL PATIENT	
		Learning Objectives	21
		Introduction	21
		Changes in the Endocrine Axes	21
		Overview	21
		Implications for Management	22
		Adrenal Insufficiency in Sepsis	23
		Hypothalamic-Pituitary-Adrenal Axis	23
		Effects of Cortisol	23
		Regulation During Critical Illness	24
		Clinical Characteristics	24
		Epidemiology	25
		Prognosis	26
		Diagnosis	26
		Treatment	28
		Historical Perspective	28
TOXICOLOGY/EMERGENCY PREPAREDNESS			
Learning Objectives	1		
Toxicology	1		
Introduction	1		
General Management	1		
Drug Screens	2		
Gastric Decontamination	2		
Antidotes	4		
Specific Poisoning Agents	4		
Acetaminophen	4		
Clinical Presentation	4		
Treatment	5		
Methanol and Ethylene Glycol	6		
Clinical Presentation	6		
Treatment	7		
Cardiovascular Drugs	7		
Poison Control Centers	8		
Emergency Preparedness	8		
Introduction	8		
Chemical Agents	8		
Vesicant or Blister Agents	8		

Current Paradigm	28
Future Direction	30
Stress Hyperglycemia	30
Physiologic Effects of Insulin	32
Mechanisms of Stress-Induced Hyperglycemia and Insulin Resistance	32
Epidemiology	32
Effects of Hyperglycemia	32
Immunomodulation	32
Outcomes Association	32
Intensive Glycemic Control	33
Rationale	33
Evidence	33
Implementation Considerations	34
Vasopressin Deficiency	38
Physiology of Vasopressin	38
Changes During Shock States	38
Historical Perspective	39
Role of Supplementation	39
Clinical Effects	39
Applications in Practice	40
Growth Hormone Supplementation	41
Rationale	41
Clinical Applications	41
Role of Pharmacists	42
Annotated Bibliography	43
Self-Assessment Questions	47

AGITATION/WITHDRAWAL SYNDROMES

Learning Objectives	51
Introduction	51
Agitation Management	51
Pathophysiology and Prognosis of Agitation	52
Sedation Assessment Scales	52
Nonpharmacological and Pharmacological Interventions	54
Nonpharmacological Interventions	55
Pharmacological Interventions	55
Sedatives	56
Analgesics	57
New Technology	58
Therapeutic Goals and Outcomes	58
Role of the Pharmacist	59
Delirium	61
Characteristics and Prognosis	61
Therapeutic Goals, Outcomes, and Treatment	61
Role of the Pharmacist	63
Withdrawal Syndromes	64
Alcohol	64
Patients With Refractory Symptoms	68
Adjunctive Therapies	68
Sedatives and Hypnotics	68
Opioids	69
Stimulants	70
Amphetamines	70
Cocaine	71

3,4-methylenedioxymethamphetamine	71
Gamma-Hydroxybutyric Acid	72
Nicotine	73
Selective Serotonin Reuptake Inhibitors	74
Anabolic Steroids	74
Therapeutic Goals and Outcomes	75
Role of the Pharmacist	75
Long-Term Consequences of the Intensive Care Unit	75
Conclusion	76
Annotated Bibliography	76
Self-Assessment Questions	79

Critical Care II

ANEMIA OF CRITICAL ILLNESS: PREVENTION AND TREATMENT

Learning Objectives	87
Introduction	87
Pathophysiology	88
Causes of Anemia in Critically Ill Patients	88
Active Bleeding	88
Phlebotomy	88
Inflammation (Anemia of Critical Illness)	88
Regulation of Erythropoiesis	88
Impaired Erythropoiesis in Critically Ill Patients	89
Inadequate Erythropoietin Production	89
Altered Iron Metabolism	90
Decreased RBC Life Cycle	90
Exacerbating Factors	91
Coagulopathy	91
Nutritional and Pharmacological Vitamin K Deficiency	91
Drug-Induced Platelet Dysfunction	91
Nutritional Deficits	91
Iron Deficiency	92
Other Nutritional Deficiencies	92
Impact of Nutritional Deficiencies	92
Complications of Anemia in Critically Ill Patients	92
Inadequate Tissue Oxygenation	92
Cardiovascular Complications	93
Diagnosis of Anemia of Critical Illness	93
Clinical Assessment	93
Laboratory Assessment	93
Treatment	94
Therapeutic Goals	94
Maintain Adequate Tissue Oxygenation and Perfusion	94
Immediate Correction of Severe Anemia	94
Prevent and Minimize Blood Loss	94
Blood Product Administration	94
Safety of Blood Product Administration	94
Therapeutic Administration of Blood Products	95
Recombinant Human Erythropoietin	95
Clinical Pharmacology	95
Use in Anemia of Critical Illness	96
Adverse Events	97

Role of the Pharmacist	98
Iron Supplementation	98
Oral Iron Supplements	98
Parenteral Iron Supplements	98
Hemostatic Drugs	99
Reversal of Drug-Induced Coagulopathies	99
Treatment of Bleeding	99
Antifibrinolytic Drugs	99
Desmopressin	100
Recombinant Activated Factor VII	100
Pharmacoeconomic Considerations	101
Patient-Specific Treatment Strategies	102
Blood Conservation Strategies	102
Conclusion	103
Annotated Bibliography	103
Self-Assessment Questions	105

SPECIAL CONSIDERATIONS IN THE MANAGEMENT OF TRAUMA PATIENTS

Learning Objectives	111
Introduction	111
Epidemiology	111
Mechanism of Injury	112
Severity of Injury	112
Pathophysiology	112
Shock	113
Alterations in Coagulation	114
Clinical Characteristics and Assessments	115
Therapeutic Goals	117
Fluid Resuscitation	117
Colloids	118
Crystalloids	118
Treatment of Bleeding	118
Blood Products	118
Surgery	119
Hemostatic Drugs	119
Desmopressin	120
Conjugated Estrogen	120
Recombinant Activated Factor VII	120
Pain Control	122
Sedation	122
Stress Ulcer Prophylaxis	123
Venous Thromboembolism Prophylaxis	123
Mechanical Prophylaxis	123
Pharmacological Prophylaxis	124
Low-Molecular-Weight Heparins	124
Heparin	124
Fondaparinux	125
Nutrition Support	125
Complications	125
Noninfectious Complications	125
Intra-Abdominal Compartment Syndrome	126
Infectious Complications	126
Ventilator-Associated Pneumonia	126
Sinusitis	127
Intra-Abdominal Infections	127

Meningitis	128
Candidiasis	128
Alterations in Pharmacokinetics	129
Drug Absorption	130
Distribution	130
Clearance	130
Aminoglycoside Antibiotics	130
β -Lactam Antibiotic Drugs	130
Drotrecogin Alfa Activated	131
Pharmacists' Role	131
Conclusion	132
Annotated Bibliography	132
Self-Assessment Questions	135

Transplantation

IMMUNOSUPPRESSIVE STRATEGIES IN SOLID ORGAN TRANSPLANTATION

Learning Objectives	141
Introduction	141
Overview of the Principles of Immunosuppression	142
Phases of Immunosuppression	142
Induction Drugs	142
Maintenance Immunosuppression	143
Treatment of Rejection	143
Traditional Immunosuppressive Regimens	144
Calcineurin Inhibitor-Based Immunosuppressive Regimens	144
Cyclosporine-Based Regimens	144
Tacrolimus-Based Regimens	144
Cyclosporine-Based Versus Tacrolimus-Based Regimens	144
Efficacy	144
Tolerability	145
Withdrawal and Avoidance Immunosuppressive Strategies	145
Rationale for Immunosuppressive Withdrawal and Avoidance Strategies	145
Calcineurin Inhibitor Withdrawal and Avoidance Strategies	146
Sirolimus	146
Pharmacokinetics	146
Adverse Effects	146
Role in Immunosuppressive Therapy	147
Mycophenolate Mofetil	148
Pharmacokinetics	148
Adverse Effects	148
Role in Immunosuppressive Therapy	149
Enteric-Coated Mycophenolate Sodium	150
Belatacept	150
Corticosteroid Withdrawal and Avoidance Strategies	150
Interleukin-2 Receptor Antagonists	151
Lymphocyte-Depleting Drugs	151
Antithymocyte Globulin	151
Alemtuzumab	152

Immunosuppressive Strategies in Special Populations	152
High Immunological Risk Transplant Recipients	152
African-American Population	152
Socioeconomic Factors	152
Genetic Factors	153
Immunosuppressive Strategies	153
Highly Sensitized Transplant Recipients	153
Retransplantation	154
Recipients of Organs from Marginal or Expanded Criteria Donor	155
Recipients of Organs from ABO-Incompatible Donors	155
Future Immunosuppressive Strategies	155
Tolerance Induction Immunosuppressive Strategies	155
Conclusion	156
Annotated Bibliography	156
Self-Assessment Questions	159

INFECTIOUS DISEASE CONCERNS IN SOLID ORGAN TRANSPLANTATION

Learning Objectives	165
Introduction	165
Direct and Indirect Effects of Post-Transplant Infection	166
Risk Factors for Post-Transplant Infections	166
Technical and Surgical Complications of the Transplant Procedure	166
Net State of Immunosuppression	167
Recipient Environmental Exposures	167
Donor Organ Exposures	167
Community and Nosocomial Exposures	168
Clinical Presentation	170
Patient Presentation	170
Initial Evaluation of Suspected Infection	170
Antimicrobial Drug Therapy for Post-Transplant Infections	170
Therapeutic Goals	170
Classification of Antimicrobial Drug Therapy	171
Prophylactic Antimicrobial Drug Therapy	171
Pre-Emptive Antimicrobial Drug Therapy	171
Therapeutic Antimicrobial Drug Therapy	171
Reduction of Immunosuppression	171
Drug Interactions	172
Epidemiology and Pathophysiology	172
Timeline of Presentation of Post-transplant Infections	172
Infections Occurring in the First Month	172
Post-Transplant	172
Liver Transplantation	173
Kidney Transplantation	173
Pancreas Transplantation	174
Heart Transplantation	174
Lung Transplantation	174
Infections Occurring 2–6 Months Post-Transplant	174

Viral Infections	174
Cytomegalovirus Infections	174
Herpes Simplex Virus and Varicella-Zoster Virus Infections	176
Fungal Infections	177
Parasitic Infections	177
<i>Pneumocystis jiroveci</i> Pneumonia	177
<i>Toxoplasma</i> Infections	178
<i>Nocardia</i> Infections	178
Infections Occurring Longer Than Six Months Post-Transplant	179
BK Virus Infection	179
Education	180
Patient Education	180
Non-Transplant Health Care Providers	180
Conclusion	180
Annotated Bibliography	180
Self-Assessment Questions	183

HEMATOPOIETIC STEM CELL TRANSPLANTATION

Learning Objectives	187
Introduction	187
History of Stem Cell Transplantation	187
Clinical Indications	187
Indications for Autologous Stem Cell Transplantation	187
Indications for Allogeneic Stem Cell Transplantation	188
Prognostic Indicators and Transplant Exclusion Criteria	188
Prognostic Indicators	188
Potential Stem Cell Transplantation Exclusion Criteria	188
Stem Cell Transplantation Preparative Regimens	188
Common Preparative Regimens for Autologous Stem Cell Transplantation	188
Common Preparative Regimens for Allogeneic Stem Cell Transplantation	189
Stem Cell Transplantation Procedures	190
Stem Cell Collection for Autologous Stem Cell Transplantation	190
Types of Allogeneic Stem Cell Transplants	190
Donor Stem Cell Collection for Allogeneic Stem Cell Transplantation	191
Stem Cell Transplantation and Engraftment	191
Acute Complications Following Stem Cell Transplantation	191
Infections During the Neutropenic Period	191
Prophylactic Strategies	192
Standard Approaches to Treatment	193
Nausea and Vomiting	193
Pathophysiology and Incidence	193
Preferred Antiemetics	194
Mucositis	195
Pathophysiology and Incidence	195
Preferred Analgesics	195

Preferred Nutrition Strategies	195
Preventing Mucositis	195
Bleeding During the Thrombocytopenic Period	195
Risk Factors	195
Role of Platelet Transfusions	196
Prevention and Treatment Options	196
Veno-Occlusive Disease	196
Pathophysiology and Incidence	196
Risk Factors	196
Clinical Manifestations and Diagnosis	196
Preventive and Treatment Options	197
Acute Graft-Versus-Host Disease Following	
Allogeneic Stem Cell Transplantation	197
Pathophysiology and Incidence	197
Risk Factors	197
Clinical Manifestations	197
Prophylaxis Strategies	198
Treatment Strategies	199
Late Complications Following Transplantation	199
Opportunistic Infections During	
Immunosuppression	199
Common Pathogens	199
Prophylaxis Strategies	200
Standard Approaches to Treatment	200
Disease Relapse	201
Chronic Graft-Versus-Host Disease Following	
Allogeneic Stem Cell Transplantation	201
Pathophysiology and Incidence	201
Clinical Manifestations	202
Prophylaxis Strategies	202
Salvage Treatment Strategies	202
Late Complications of Stem Cell Transplantation	203
Pulmonary Effects	203
Infertility	203
Secondary Malignancies	203
Conclusion	203
Annotated Bibliography	204
Self-Assessment Questions	207